Konzern Holding

Konzern Group is a Chinese pharmaceutical and biotechnology company that specializes in the development, manufacture, and distribution of a wide range of healthcare products, including dietary supplements, traditional Chinese medicines (TCM), and recombinant enzymes. Headquartered in Guangzhou, the company operates through several key subsidiaries such as Guangzhou Konzern Biotech and Guangzhou LifeTech Pharmaceutical, and maintains an extensive distribution network across more than 28 provinces in China. Konzern Group is particularly noted for its Cowinzym (Aflatoxin-detoxifizyme) project, a biotechnology initiative aimed at neutralizing toxins in food and feed, which was supported by China's National 863 Program. The company gained international prominence following its reverse merger with China Medicine Corporation, which provided it with a platform for global expansion and investment.